Skip to main content
Midas Edge

ReShape Lifesciences Inc

For the period ended Sep 30, 2024. Filed Nov 14, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 14, 2024

HIND$1.59+0.6%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Table of Contents

INDEX

​
PART I – FINANCIAL INFORMATION
​
Item 1.Condensed Consolidated Financial Statements (unaudited)3
​Condensed Consolidated Balance Sheets as of September 30, 2024 and December 31, 20233
​Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2024 and 20234
​Condensed Consolidated Statements of Comprehensive Loss for the three and nine months ended September 30, 2024 and 20235
​Condensed Consolidated Statements of Stockholders’ Equity for the three and nine months ended September 30, 2024 and 20236
​Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2024 and 20238
​Notes to Condensed Consolidated Financial Statements9
Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations20
Item 3.Quantitative and Qualitative Disclosures About Market Risk27
Item 4.Controls and Procedures27
​
PART II – OTHER INFORMATION
​
Item 1.Legal Proceedings28
Item 1A.Risk Factors29
Item 2.Unregistered Sales of Equity Securities and Use of Proceeds30
Item 3.Defaults Upon Senior Securities31
Item 4.Mine Safety Disclosures31
Item 5.Other Information31
Item 6.Exhibits32
SIGNATURES33
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.